Mikołaj Jońca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mikołaj Jońca has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Natasza Kurys
Medical University of Lodz, Aleja T. Kościuszki 4, 90–419 Łódź, Poland
9 shared publications - Adam Kubisa
Pomeranian Medical University, ul. Rybacka 1, 70-204 Szczecin, Poland
6 shared publications - Aleksandra Dybcio
Medical University of Lublin
6 shared publications - Dorota Szydłowska
Opole University
6 shared publications - Julia Kupczak
Łazarski University
6 shared publications - Katarzyna Kupczyk
Southern Hospital in Warsaw
6 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 75016
Avacincaptad pegol: New therapy for geographic atrophy in age-related macular degeneration
Geographic atrophy (GA) is still an important global health concern, especially for patients over 50 years, as it represents a late stage of dry age-related macular degeneration (AMD) and accounts for a large portion of permanent central vision loss. The pathogenesis of GA is complex and multifactorial, including oxidative stress, chronic inflammation, abnormalities in the vitamin A visual cycle and progressive disfunction of the retinal pigment epithelium (RPE). The chronic activation of the complement system, particularly the alternative pathway, is fundamental in the degeneration of RPE cells and photoreceptors. In addition, genetic factors, in particular genetic variants of complement regulatory genes, further increase the risk of disease and can accelerate its progression. Until recently, treatment options were limited to antioxidant supplements based on Age-Related Eye Disease Study (AREDS and AREDS2) recommendations, which demonstrated average effectiveness in slowing disease progression. However, the emergence of medications targeting the complement system marked a turning point. Pegcetacoplan, the C3 inhibitor, and avacincaptad pegol, the C5 inhibitor, have been shown to slow down GA the progression. Although these drugs do not improve visual acuity, they change the natural course of the disease. The difference in the target of the complement cascade may influence the safety of treatment. However, there is still a need for further research to optimize treatment and individualize therapy for patients with GA.
- 18 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 75016
Open AccessAvacincaptad pegol: New therapy for geographic atrophy in age-related macular degeneration
Geographic atrophy (GA) is still an important global health concern, especially for patients over 50 years, as it represents a late stage of dry age-related macular degeneration (AMD) and accounts for a large portion of permanent central vision loss. The pathogenesis of GA is complex and multifactorial, including oxidative stress, chronic inflammation, abnormalities in the vitamin A visual cycle and progressive disfunction of the retinal pigment epithelium (RPE). The chronic activation of the complement system, particularly the alternative pathway, is fundamental in the degeneration of RPE cells and photoreceptors. In addition, genetic factors, in particular genetic variants of complement regulatory genes, further increase the risk of disease and can accelerate its progression. Until recently, treatment options were limited to antioxidant supplements based on Age-Related Eye Disease Study (AREDS and AREDS2) recommendations, which demonstrated average effectiveness in slowing disease progression. However, the emergence of medications targeting the complement system marked a turning point. Pegcetacoplan, the C3 inhibitor, and avacincaptad pegol, the C5 inhibitor, have been shown to slow down GA the progression. Although these drugs do not improve visual acuity, they change the natural course of the disease. The difference in the target of the complement cascade may influence the safety of treatment. However, there is still a need for further research to optimize treatment and individualize therapy for patients with GA.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
THE RISE OF ADULT ADHD DIAGNOSIS: AWARENESS OR OVERDIAGNOSIS
Background. In the early 2020s, the global ADHD landscape shifted radically, marked by surging public interest, social media discourse, and rising diagnosis rates. The review investigates whether it reflects enhanced clinical awareness or a trend toward overdiagnosis. Comparing diagnostic trajectories, the study addresses the issue of overdiagnosis in certain populations and persistent underdiagnosis in others, followed by age and gender influence prevalence rates. Aim. The study aims to analyze epidemiological trends in ADHD diagnosis among children and adults, assesses overdiagnosis and underdiagnosis, and identify challenges in the diagnostic process along with factors influencing current diagnostic trends. Material and methods. A literature review was conducted using PubMed, Frontiers, and Google Scholar. The analysis was grounded in DSM-5 criteria, Conners 3, and DIVA-5 questionnaires. NICE guidelines were incorporated to evaluate methodological rigor and temporal demands required for valid clinical assessments. Results. Data indicate an increase in ADHD diagnoses from 6.1% in 1997 to 10.2% in 2016. Longitudinal analysis reveals an escalation linked to the COVID-19 pandemic. Pre-pandemic, adult diagnoses averaged 8.8 per 100,000 population monthly. During 2020–2021, this rose to 19.2/100,000 (a 4.9% month-over-month increase). Post-pandemic reached an average of 34.8/100,000. Conclusions. Despite the noticeable increase in diagnostic rates reported in clinical settings, there remains a lack of solid epidemiological evidence demonstrating a rise in the prevalence of ADHD within the general population within the last decade. Currently, the data does not support a rise in ADHD prevalence, rather it reflects shifts in awareness, diagnostic practices, and health-care seeking behaviors.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessTHE RISE OF ADULT ADHD DIAGNOSIS: AWARENESS OR OVERDIAGNOSIS
Background. In the early 2020s, the global ADHD landscape shifted radically, marked by surging public interest, social media discourse, and rising diagnosis rates. The review investigates whether it reflects enhanced clinical awareness or a trend toward overdiagnosis. Comparing diagnostic trajectories, the study addresses the issue of overdiagnosis in certain populations and persistent underdiagnosis in others, followed by age and gender influence prevalence rates. Aim. The study aims to analyze epidemiological trends in ADHD diagnosis among children and adults, assesses overdiagnosis and underdiagnosis, and identify challenges in the diagnostic process along with factors influencing current diagnostic trends. Material and methods. A literature review was conducted using PubMed, Frontiers, and Google Scholar. The analysis was grounded in DSM-5 criteria, Conners 3, and DIVA-5 questionnaires. NICE guidelines were incorporated to evaluate methodological rigor and temporal demands required for valid clinical assessments. Results. Data indicate an increase in ADHD diagnoses from 6.1% in 1997 to 10.2% in 2016. Longitudinal analysis reveals an escalation linked to the COVID-19 pandemic. Pre-pandemic, adult diagnoses averaged 8.8 per 100,000 population monthly. During 2020–2021, this rose to 19.2/100,000 (a 4.9% month-over-month increase). Post-pandemic reached an average of 34.8/100,000. Conclusions. Despite the noticeable increase in diagnostic rates reported in clinical settings, there remains a lack of solid epidemiological evidence demonstrating a rise in the prevalence of ADHD within the general population within the last decade. Currently, the data does not support a rise in ADHD prevalence, rather it reflects shifts in awareness, diagnostic practices, and health-care seeking behaviors.
- Open Access
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
A COMPREHENSIVE REVIEW OF CAR-T CELL THERAPY ACROSS RHEUMATIC DISEASES
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematological malignancies, has appeared as a promising strategy to achieve the sustained depletion of pathogenic immune cells in rheumatology. Objective: This review critically synthesizes current evidence regarding the pathophysiological mechanisms, molecular designs, clinical efficacy, and toxicity profiles of CAR-T therapy across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), and adult-onset Still's disease (AOSD). Methods: 77 peer-reviewed sources, including clinical trials, preclinical models, and case series, were analyzed and objectively categorized by target antigens, cellular modifications, and clinical endpoints. Results: CD19-directed CAR-T cells successfully penetrate inflamed tissues and deplete the autoreactive B-cell compartment, resulting in measurable clinical remission in highly refractory SLE, SSc, and IIM cohorts.This enables the complete discontinuation of concurrent immunosuppressive drugs. Due to a complex, hypoxic synovial microenvironment, targeted RA treatment needs advanced approaches, such as fourth-generation CARs and in vivo generation techniques. Therapy-associated toxicities, primarily cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), generally present with significantly lower clinical severity in ARD patients compared to heavily pre-treated oncological cohorts. Conclusion: CAR-T cell therapy represents a fundamental paradigm shift in the management of severe ARD, shifting the objective from chronic immunosuppression to definitive immune reconstitution. Despite logistical, financial, and safety challenges, clinical efficacy in treatment-refractory cases remains exceptionally high.
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessA COMPREHENSIVE REVIEW OF CAR-T CELL THERAPY ACROSS RHEUMATIC DISEASES
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematological malignancies, has appeared as a promising strategy to achieve the sustained depletion of pathogenic immune cells in rheumatology. Objective: This review critically synthesizes current evidence regarding the pathophysiological mechanisms, molecular designs, clinical efficacy, and toxicity profiles of CAR-T therapy across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), and adult-onset Still's disease (AOSD). Methods: 77 peer-reviewed sources, including clinical trials, preclinical models, and case series, were analyzed and objectively categorized by target antigens, cellular modifications, and clinical endpoints. Results: CD19-directed CAR-T cells successfully penetrate inflamed tissues and deplete the autoreactive B-cell compartment, resulting in measurable clinical remission in highly refractory SLE, SSc, and IIM cohorts.This enables the complete discontinuation of concurrent immunosuppressive drugs. Due to a complex, hypoxic synovial microenvironment, targeted RA treatment needs advanced approaches, such as fourth-generation CARs and in vivo generation techniques. Therapy-associated toxicities, primarily cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), generally present with significantly lower clinical severity in ARD patients compared to heavily pre-treated oncological cohorts. Conclusion: CAR-T cell therapy represents a fundamental paradigm shift in the management of severe ARD, shifting the objective from chronic immunosuppression to definitive immune reconstitution. Despite logistical, financial, and safety challenges, clinical efficacy in treatment-refractory cases remains exceptionally high.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
COBENFY - A NEW ANTIPSYCHOTIC DRUG
Antipsychotic medications are the cornerstone of schizophrenia treatment and are traditionally classified into first-, second, and third-generation agents according to their pharmacological properties and mechanism of action. While these drugs effectively control psychotic symptoms through dopamine receptor antagonism or partial agonism, their clinical use is frequently limited by extrapyramidal symptoms, metabolic disturbances, hyperprolactinaemia, and inadequate efficacy against negative and cognitive symptoms. Cobenfy (xanomeline–trospium), approved by the U.S. Food and Drug Administration in 2024, represents the first antipsychotic with a non-dopaminergic mechanism of action. It combines xanomeline, a centrally acting muscarinic M1/M4 receptor agonist, with trospium chloride, a peripherally acting muscarinic antagonist that reduces cholinergic adverse effects without crossing the blood–brain barrier. This review summarizes the pharmacology, mechanism of action, pharmacokinetics, clinical efficacy, safety, and therapeutic role of Cobenfy based on available preclinical and clinical evidence. Phase II and III studies, including the EMERGENT clinical program, demonstrated significant improvements in Positive and Negative Syndrome Scale scores, sustained long-term efficacy, and a favourable metabolic profile with minimal effects on body weight and cardiometabolic parameters. Preliminary findings also suggest potential benefits for negative symptoms and cognitive impairment. Rather than replacing established antipsychotics, it expands current treatment options by introducing a novel cholinergic therapeutic strategy. Ongoing comparative, long-term, and real-world studies will further define its role in schizophrenia management and its potential application in other neuropsychiatric disorders, including Alzheimer's disease–related psychosis.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessCOBENFY - A NEW ANTIPSYCHOTIC DRUG
Antipsychotic medications are the cornerstone of schizophrenia treatment and are traditionally classified into first-, second, and third-generation agents according to their pharmacological properties and mechanism of action. While these drugs effectively control psychotic symptoms through dopamine receptor antagonism or partial agonism, their clinical use is frequently limited by extrapyramidal symptoms, metabolic disturbances, hyperprolactinaemia, and inadequate efficacy against negative and cognitive symptoms. Cobenfy (xanomeline–trospium), approved by the U.S. Food and Drug Administration in 2024, represents the first antipsychotic with a non-dopaminergic mechanism of action. It combines xanomeline, a centrally acting muscarinic M1/M4 receptor agonist, with trospium chloride, a peripherally acting muscarinic antagonist that reduces cholinergic adverse effects without crossing the blood–brain barrier. This review summarizes the pharmacology, mechanism of action, pharmacokinetics, clinical efficacy, safety, and therapeutic role of Cobenfy based on available preclinical and clinical evidence. Phase II and III studies, including the EMERGENT clinical program, demonstrated significant improvements in Positive and Negative Syndrome Scale scores, sustained long-term efficacy, and a favourable metabolic profile with minimal effects on body weight and cardiometabolic parameters. Preliminary findings also suggest potential benefits for negative symptoms and cognitive impairment. Rather than replacing established antipsychotics, it expands current treatment options by introducing a novel cholinergic therapeutic strategy. Ongoing comparative, long-term, and real-world studies will further define its role in schizophrenia management and its potential application in other neuropsychiatric disorders, including Alzheimer's disease–related psychosis.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging. It is characterized by cognitive decline, functional impairment, and significant public health burden. Pathophysiology involves a complex interplay of amyloid-β (Aβ) accumulation, tau pathology and neuroinflammation. Despite extensive research, current pharmacological management of Alzheimer’s disease relies primarily on symptomatic therapies and does not alter the underlying neurodegenerative process. The aim of this review is to summarize the current state of knowledge on therapeutic strategies for AD, with particular emphasis on lecanemab, a recombinant humanized antibody characterized by their selectivity for soluble Aβ oligomers. We discuss its mechanism of action, clinical evidence from recent randomized controlled trials assessing its efficacy and safety. In this review, lecanemab is not only addressed in the context of established and widely used therapies but also alongside novel treatments currently being tested. Lecanemab represents a significant step towards disease-modifying therapy for AD as it reduces brain amyloid. Although the available results are promising, current evidence suggests that monotherapeutic interventions targeting a single pathological mechanism may be insufficient to completely stop or reverse disease progression underscoring the need for further research to optimize therapeutic outcomes.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessTHERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging. It is characterized by cognitive decline, functional impairment, and significant public health burden. Pathophysiology involves a complex interplay of amyloid-β (Aβ) accumulation, tau pathology and neuroinflammation. Despite extensive research, current pharmacological management of Alzheimer’s disease relies primarily on symptomatic therapies and does not alter the underlying neurodegenerative process. The aim of this review is to summarize the current state of knowledge on therapeutic strategies for AD, with particular emphasis on lecanemab, a recombinant humanized antibody characterized by their selectivity for soluble Aβ oligomers. We discuss its mechanism of action, clinical evidence from recent randomized controlled trials assessing its efficacy and safety. In this review, lecanemab is not only addressed in the context of established and widely used therapies but also alongside novel treatments currently being tested. Lecanemab represents a significant step towards disease-modifying therapy for AD as it reduces brain amyloid. Although the available results are promising, current evidence suggests that monotherapeutic interventions targeting a single pathological mechanism may be insufficient to completely stop or reverse disease progression underscoring the need for further research to optimize therapeutic outcomes.
- Open Access
- 25 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
ERENUMAB, A NEW PREVENTIVE TREATMENT FOR MIGRAINE: MECHANISM OF ACTION, SAFETY AND EFFICACY
Background: Migraine is a common, debilitating and one of the most disabling of the neurovascular disorders. The common treatment has been based on non-specific medications derived from other clinical disciplines such as beta-blockers, antiepileptics and antidepressants, which have variable efficacy and many unwanted side effects and are therefore frequently discontinued. The recent knowledge about the involvement of CGRP and its receptors in migraine pathophysiology has opened new avenues for anti-migraine treatment. Objectives: The aim of this paper is to comprehensively review the mechanism of action, clinical efficacy, safety profile, and comparative effectiveness of erenumab - the first fully human monoclonal antibody designed specifically for migraine prevention. Methods: A narrative review of the current medical literature was conducted using the PubMed database. The analysis included data from phase 2, 3 and 4 randomized controlled trials, long-term open-label extensions, and current international neurological guidelines. Results: Erenumab is a monoclonal antibody that selectively targets the canonical CGRP receptor and functions as a competitive receptor antagonist. Binding of erenumab to the CGRP receptor does not result in vasoconstriction and does not interact with the CYP450 enzyme system. Studies including STRIVE, ARISE and LIBERTY trials have demonstrated the high efficacy of erenumab in the reduction of MMD in both EM and CM patients, including those who have failed multiple prior prophylactic treatments. The HER-MES trial has further confirmed the high tolerability of erenumab and a higher retention rate compared to topiramate. The safety profile is highly favorable, with injection site reactions and constipation being the most frequently reported adverse events. Furthermore, erenumab can safely be given alongside with novel acute treatments, such as gepants and ditans. Conclusions: Erenumab holds great promise in migraine prophylaxis as it’s offering a targeted, highly effective, and well-tolerated therapeutic option. Future research should focus on its long-term efficacy in a real-world setting. One important aspect will be to explore its safety during pregnancy and in children. An interesting and potentially clinically useful aspect for non-responders will be exploring the possibility of combining it with antibodies against other neuropeptide pathways, such as those involving PACAP.
- 25 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessERENUMAB, A NEW PREVENTIVE TREATMENT FOR MIGRAINE: MECHANISM OF ACTION, SAFETY AND EFFICACY
Background: Migraine is a common, debilitating and one of the most disabling of the neurovascular disorders. The common treatment has been based on non-specific medications derived from other clinical disciplines such as beta-blockers, antiepileptics and antidepressants, which have variable efficacy and many unwanted side effects and are therefore frequently discontinued. The recent knowledge about the involvement of CGRP and its receptors in migraine pathophysiology has opened new avenues for anti-migraine treatment. Objectives: The aim of this paper is to comprehensively review the mechanism of action, clinical efficacy, safety profile, and comparative effectiveness of erenumab - the first fully human monoclonal antibody designed specifically for migraine prevention. Methods: A narrative review of the current medical literature was conducted using the PubMed database. The analysis included data from phase 2, 3 and 4 randomized controlled trials, long-term open-label extensions, and current international neurological guidelines. Results: Erenumab is a monoclonal antibody that selectively targets the canonical CGRP receptor and functions as a competitive receptor antagonist. Binding of erenumab to the CGRP receptor does not result in vasoconstriction and does not interact with the CYP450 enzyme system. Studies including STRIVE, ARISE and LIBERTY trials have demonstrated the high efficacy of erenumab in the reduction of MMD in both EM and CM patients, including those who have failed multiple prior prophylactic treatments. The HER-MES trial has further confirmed the high tolerability of erenumab and a higher retention rate compared to topiramate. The safety profile is highly favorable, with injection site reactions and constipation being the most frequently reported adverse events. Furthermore, erenumab can safely be given alongside with novel acute treatments, such as gepants and ditans. Conclusions: Erenumab holds great promise in migraine prophylaxis as it’s offering a targeted, highly effective, and well-tolerated therapeutic option. Future research should focus on its long-term efficacy in a real-world setting. One important aspect will be to explore its safety during pregnancy and in children. An interesting and potentially clinically useful aspect for non-responders will be exploring the possibility of combining it with antibodies against other neuropeptide pathways, such as those involving PACAP.
- Open Access
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
EVINACUMAB, A NEW TREATMENT FOR FAMILIAL HYPERCHOLESTEROLAEMIA: MECHANISM OF ACTION, SAFETY AND EFFICACY
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels and a markedly increased risk of premature atherosclerotic cardiovascular disease. The aim of this review was to summarize current knowledge on the pathophysiology, diagnosis, and management of HoFH, with particular emphasis on angiopoietin-like protein 3 (ANGPTL3) inhibition and the clinical role of evinacumab. A comprehensive analysis of published clinical trials, guidelines, and observational studies was conducted to evaluate available diagnostic criteria and therapeutic strategies. Standard lipid-lowering therapies often fail to achieve recommended LDL-C targets in HoFH due to impaired LDL receptor function. Evinacumab, a fully human monoclonal antibody targeting ANGPTL3, has demonstrated substantial LDL-C reductions independent of LDL receptor activity in both adult and pediatric patients. Clinical studies report LDL-C reductions of approximately 45–50%, along with a favorable safety profile. In conclusion, ANGPTL3 inhibition with evinacumab represents a significant advancement in the treatment of HoFH, offering an effective therapeutic option for patients with inadequate response to conventional lipid-lowering therapies.
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessEVINACUMAB, A NEW TREATMENT FOR FAMILIAL HYPERCHOLESTEROLAEMIA: MECHANISM OF ACTION, SAFETY AND EFFICACY
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels and a markedly increased risk of premature atherosclerotic cardiovascular disease. The aim of this review was to summarize current knowledge on the pathophysiology, diagnosis, and management of HoFH, with particular emphasis on angiopoietin-like protein 3 (ANGPTL3) inhibition and the clinical role of evinacumab. A comprehensive analysis of published clinical trials, guidelines, and observational studies was conducted to evaluate available diagnostic criteria and therapeutic strategies. Standard lipid-lowering therapies often fail to achieve recommended LDL-C targets in HoFH due to impaired LDL receptor function. Evinacumab, a fully human monoclonal antibody targeting ANGPTL3, has demonstrated substantial LDL-C reductions independent of LDL receptor activity in both adult and pediatric patients. Clinical studies report LDL-C reductions of approximately 45–50%, along with a favorable safety profile. In conclusion, ANGPTL3 inhibition with evinacumab represents a significant advancement in the treatment of HoFH, offering an effective therapeutic option for patients with inadequate response to conventional lipid-lowering therapies.
- Open Access
- 7 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 91
Role Of Pelvic Floor Muscle Training In Women’s Health And Quality Of Life A Narrative Review
Introduction: Pelvic floor muscle dysfunction disorders are a widespread and frequently undiagnosed health problem among women across all age groups. They can result in urinary and fecal incontinence, pelvic organ prolapse, and chronic pain, significantly reducing women’s quality of life. Conservative treatment, particularly pelvic floor muscle training (PFMT), is currently recognized as a highly effective first-line therapy. Purpose: This review aims to present the role of pelvic floor muscle training (PFMT) in improving women’s health and quality of life, with a particular focus on the effectiveness of this form of therapy in the prevention and treatment of pelvic floor muscle dysfunction disorders. A brief description of the state of knowledge: The pelvic floor muscles are crucial for holding urine and stool, keeping the pelvic organs in place, and supporting sexual function. Their dysfunction is linked to many risk factors, such as age, vaginal delivery, obesity, and lifestyle. Pelvic floor muscle training (PFMT) improves muscle tone and strength, leading to reduced symptoms, most commonly urinary incontinence. Pelvic floor muscle training (PFMT) also contributes to improving quality of life in physical, mental, and social dimensions. Biofeedback or electrostimulation are supportive methods, which can further enhance the effectiveness of therapy. Conclusions: Pelvic floor muscle training (PFMT) is an effective and safe method for the prevention and treatment of pelvic floor dysfunction disorders in women. It contributes to a significant improvement in symptoms and quality of life. An individualized and holistic approach to the patient is recommended, incorporating education and a supervised exercise program to ensure the effectiveness of therapy.
- 7 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 91
Open AccessRole Of Pelvic Floor Muscle Training In Women’s Health And Quality Of Life A Narrative Review
Introduction: Pelvic floor muscle dysfunction disorders are a widespread and frequently undiagnosed health problem among women across all age groups. They can result in urinary and fecal incontinence, pelvic organ prolapse, and chronic pain, significantly reducing women’s quality of life. Conservative treatment, particularly pelvic floor muscle training (PFMT), is currently recognized as a highly effective first-line therapy. Purpose: This review aims to present the role of pelvic floor muscle training (PFMT) in improving women’s health and quality of life, with a particular focus on the effectiveness of this form of therapy in the prevention and treatment of pelvic floor muscle dysfunction disorders. A brief description of the state of knowledge: The pelvic floor muscles are crucial for holding urine and stool, keeping the pelvic organs in place, and supporting sexual function. Their dysfunction is linked to many risk factors, such as age, vaginal delivery, obesity, and lifestyle. Pelvic floor muscle training (PFMT) improves muscle tone and strength, leading to reduced symptoms, most commonly urinary incontinence. Pelvic floor muscle training (PFMT) also contributes to improving quality of life in physical, mental, and social dimensions. Biofeedback or electrostimulation are supportive methods, which can further enhance the effectiveness of therapy. Conclusions: Pelvic floor muscle training (PFMT) is an effective and safe method for the prevention and treatment of pelvic floor dysfunction disorders in women. It contributes to a significant improvement in symptoms and quality of life. An individualized and holistic approach to the patient is recommended, incorporating education and a supervised exercise program to ensure the effectiveness of therapy.
- Open Access
- 10 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 90
Klinefelter Syndrome – Etiology, Clinical Presentation and Modern Approaches to the Diagnosis and Treatment: A Literature Review
Introduction: Klinefelter syndrome is the most common chromosomal abnormality in males, characterized by the presence of an extra X chromosome, resulting in 47, XXY karyotype. Its prevalence is approximately 1 in 500 to 1 in 1,000 live-born males. The phenotypic expression is highly variable and includes hypogonadism, infertility, and an increased risk of metabolic complications and neurocognitive disorders. Purpose: The aim of this review is to provide a comprehensive synthesis of the current state of knowledge on Klinefelter syndrome, with particular emphasis on modern diagnostic and therapeutic approaches. Material and methods: This article is a narrative literature review and was conducted using international databases. Publications were selected based on their scientific value, relevance, and relation to the topic. Results: Current evidence indicates that patients benefit from an interdisciplinary approach, involving coordinated care among multiple specialists, including andrologists, endocrinologists, geneticists, psychologists, and experts in infertility treatment. Despite its relatively high prevalence, a significant proportion of affected individuals remain undiagnosed until adulthood, resulting in delayed initiation of therapeutic interventions. Conclusions: Klinefelter syndrome is a genetic condition with numerous somatic, reproductive, and psychosocial consequences. Early diagnosis, individualized therapeutic strategies, and multidisciplinary care significantly improve long-term prognosis and quality of life in patients. Future research should prioritize the refinement of diagnostic approaches, elucidation of the long-term effects of hormone therapy, and investigation of the molecular mechanisms underlying phenotypic variability.
- 10 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 90
Open AccessKlinefelter Syndrome – Etiology, Clinical Presentation and Modern Approaches to the Diagnosis and Treatment: A Literature Review
Introduction: Klinefelter syndrome is the most common chromosomal abnormality in males, characterized by the presence of an extra X chromosome, resulting in 47, XXY karyotype. Its prevalence is approximately 1 in 500 to 1 in 1,000 live-born males. The phenotypic expression is highly variable and includes hypogonadism, infertility, and an increased risk of metabolic complications and neurocognitive disorders. Purpose: The aim of this review is to provide a comprehensive synthesis of the current state of knowledge on Klinefelter syndrome, with particular emphasis on modern diagnostic and therapeutic approaches. Material and methods: This article is a narrative literature review and was conducted using international databases. Publications were selected based on their scientific value, relevance, and relation to the topic. Results: Current evidence indicates that patients benefit from an interdisciplinary approach, involving coordinated care among multiple specialists, including andrologists, endocrinologists, geneticists, psychologists, and experts in infertility treatment. Despite its relatively high prevalence, a significant proportion of affected individuals remain undiagnosed until adulthood, resulting in delayed initiation of therapeutic interventions. Conclusions: Klinefelter syndrome is a genetic condition with numerous somatic, reproductive, and psychosocial consequences. Early diagnosis, individualized therapeutic strategies, and multidisciplinary care significantly improve long-term prognosis and quality of life in patients. Future research should prioritize the refinement of diagnostic approaches, elucidation of the long-term effects of hormone therapy, and investigation of the molecular mechanisms underlying phenotypic variability.